Skip to main content
. Author manuscript; available in PMC: 2013 May 24.
Published in final edited form as: Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):29–34. doi: 10.1097/PAI.0b013e3181ae9e82

TABLE 2.

Clinicopathologic Characteristics, Serum Anti-HCV, and HCV NS3 Immunostaining in Serum HCV-RN Positive B-cell Non-Hodgkin Lymphoma Patients (n = 39)

Patient
Number
Age (y) Sex EN Diagnosis Serum
Anti-HCV
HCV-NS3
Protein
1 68 M No SLL +
2 39 M No DLBCL +
3 50 M No FL +
4 57 F No DLBCL +
5 71 M Yes DLBCL +
6 51 M Yes DLBCL +
7 41 M No DLBCL +
8 56 F No TCRLBL +
9 51 F Yes DLBCL +
10 69 M No DLBCL
11 30 M No DLBCL +
12 58 F No DLBCL +
13 68 M No DLBCL +
14 27 M No DLBCL +
15 60 F No DLBCL + +
16 52 F No TCRLBL +
17 34 F Yes DLBCL + +
18 48 M No DLBCL +
19 52 F No DLBCL +
20 72 M No DLBCL +
21 38 M Yes FL +
22 40 M No DLBCL +
23 56 F No DLBCL +
24 62 M No SLL + +
25 51 M Yes DLBCL + +
26 53 F No MZL +
27 68 M No FL +
28 53 M No DLBCL + +
29 68 F No DLBCL + +
30 53 F No FL +
31 51 F No DLBCL +
32 63 M No DLBCL +
33 59 F Yes DLBCL +
34 74 M No FL +
35 48 F No FL + +
36 55 M No FL +
37 61 F No SLL +
38 55 F No DLBCL + +
39 41 M No DLBCL +

DLBCL indicates diffuse large B-cell lymphoma; EN, extranodal presentation; F, female; FL, follicular lymphoma; HCV, hepatitis C virus; M, male; MZL, marginal zone lymphoma; SLL, small lymphocytic lymphoma; TCRLBL, T-cell rich large B-cell lymphoma.